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Abstract
OBJECTIVE: To investigate the effect of Soothing
liver therapy on infertile women undergoing in vi-
tro fertilization and embryo transfer (IVF-ET) and to
explore its mechanism.
METHODS: Fifty-eight women with tubal infertility
were randomized into two groups: 30 in an experi-
mental group treated with Xiaoyao powder
(Shugan) plus gonadotropin-releasing hormone an-
alog (GnRHa)/follicle-stimulating hormone (FSH)/
human chorionic gonadotropin (hCG) and 28 in the
control group who were treated with GnRHa/FSH/
hCG only. The total gonadotropin (Gn) doses re-
quired, endometrial thickness, oocyte numbers,
high quality embryo production rate and pregnan-
cy rate of the two groups were compared. The con-
centration of growth differentiation factor-9
(GDF-9) in follicular fluid was detected by western
blotting and the expression of GDF-9 mRNA in
granulosa cells was measured using reverse tran-
scription-polymerase chain reaction amplification.
RESULTS: In the experimental group, the Gn dose
was significantly lower than that in the control
group; the endometrial thickness, high quality em-
bryo production and pregnancy rates were signifi-
cantly higher and the expression of GDF-9 mRNA
was also significantly higher than in the control
group (all P<0.05).
CONCLUSION: Shugan treatment can improve the
pregnancy rate of women with tubal infertility; its
mechanism is possibly related to the increased ex-
pression of GDF-9 in granulosa cells.
© 2013 JTCM. All rights reserved.
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INTRODUCTION
In the 21st century, the number of couples with infer-
tility has increased steadily.1 According to one report,
the incidence of infertility is 11%-15% among couples
of childbearing age.2 In recent years, in vitro fertiliza-
tion and embryo transfer (IVF-ET) has become one of
the main treatments for tubal infertility.3 However,
IVF-ET has shortfalls such as a relatively low success
rate and high miscarriage rate.4 In Traditional Chinese
Medicine theory, infertility is closely associated with
stagnation of liver-Qi.5 Dispersing such stagnated liv-
er-Qi has had remarkable curative effects.6,7
It is evident that oocyte quality is closely associated
with the success of fertilization, embryonic develop-
ment and pregnancy.8 Recent research showed that
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growth differentiation factor-9 (GDF-9) is a key regula-
tory factor in the development of ovarian follicles in
the mouse.9 Thus, follicular development in GDF-9
mutant female mice stagnated at the primary stage and
resulted in complete sterility.10 Therefore, in this paper
we aimed to observe the effect of the herbal medicine
Soothing liver therapy on women with tubal infertility
from the aspect of GDF-9 and to explore its mecha-
nisms.
MATERIALS ANDMETHODS
Clinical data
In this study, 58 women with tubal infertility under-
went IVF-ET from February 2010 to October 2011 in
the Bethune International Peace Hospital. The subjects
complied with the definition of tubal infertility accord-
ing to Williams Gynecology, and liver stagnation syn-
drome criteria according to Gynecology of Chinese
Medicine.11,12 All of these patients were aged ≥35 years
with a basal follicle-stimulating hormone (FSH) level
of <10 mIU/mL, endometrial thickness ≥8 mm and
had husbands with basically normal semen. We exclud-
ed women when they presented with the following: se-
vere uterine diseases that did not allow pregnancy, se-
vere mental disorders, urinary system infections, sexual-
ly transmitted diseases, drug addiction and other seri-
ous bad habits, exposure to teratogenic X-rays, endo-
metriosis, endometrial lesions, polycystic ovary syn-
drome, or unilateral or bilateral hydrosalpinges with-
out treatment. The experimental design was approved
by the Ethics Committee of the Bethune International
Peace Hospital and performed in accordance with its
ethical standards. All subjects signed an informed con-
sent form prior to enrolment in the study.
Methods
The 58 infertile women included were randomized in-
to two groups according to a random number table
(Figure 1). An experimental group of 30 women was
treated with Xiaoyao powder and controlled ovarian hy-
perstimulation, while the control group of 28 women
was treated simply with controlled ovarian hyperstimu-
lation.
A long-term gonadotropin-releasing hormone (GnRH)
downregulation protocol was used in both groups. All
the patients were injected with 0.1 mg per day of Trip-
torelin (gonadotropin-releasing hormone agonist, Gn-
RHa, BOP-Ipsen Pharmaceutical Co., Ltd., Tianjin,
China) in the prior mid-luteal phase of the menstrual
cycle until the serum hormone levels declined to the
downregulation criteria of estrogen (E2) <50 pg/mL, lu-
teinizing hormone (LH) <3 mIU/mL, and an endome-
trial thickness <5 mm. The women were then adminis-
tered 150-300 IU Recombinant Human Follitropin Al-
fa Solution for Injection (Gonal-F, Merck Serono SPA,
Rome, Italy) by daily abdominal subcutaneous injec-
Randomized groups (n=2)
Allocated to experimental group
(n=30)
Received allocated intervention
(n=30)
Excluded (n=5)
Not meeting inclusion
criteria (n=0)
Declined to participate (n=3)
Other reasons (n=2)
Assessed for eligibility (n=63)
Lost to follow-up (n=0)
Discontinued intervention
(n=0)
Lost to follow-up (n=0)
Discontinued intervention
(n=0)
Analyzed (n=30)
Excluded from analysis (n=0)
Analyzed (n=28)
Excluded from analysis (n=0)
Figure 1 Flow diagram of randomized controlled trial for Shugan (liver soothing) used in patients undergoing IVF-ET
IVF-ET：in vitro fertilization and embryo transfer.
Allocated to experimental group
(n=28)
Received allocated intervention
(n=28)
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tions to promote follicular growth according to age, an-
tral follicle count (AFC) and basal serum FSH, FSH/
LH and E2 levels. During Gonal-F stimulation we
monitored follicular development by ultrasound exami-
nation and by observing the levels of E2, Progesterone
(P) and LH to regulate the dose of Gonal-F until more
than three follicles measuring ≥18 mm were seen in
both ovaries. The use of Gonal-F and Triptorelin was
stopped on the evening of the same day, and 250 mg
of human chorionic gonadotropin (hCG; Merck Sero-
no SPA) was administered by intramuscular injection.
After 35-36 h, oocytes were recovered by transvaginal
puncture using a 17 G Wallace ovum pick-up needle
(K-OSN-1735-A-90, Cook Ob/Gyn, Spencer, IN,
USA) guided using transvaginal ultrasonography (Sam-
sung Medison Co. Ltd., Seoul, South Korea).
Follicular aspirates were examined and oocyte-coro-
na-cumulus complexes were incubated at 37℃ , in a
5% CO2 incubator (MCO-5AC, Sanyo Corporation,
Tokyo Japan) in routine culture medium
(Quinn's-1020, SAGE BioPharma, Bedminster, NJ,
USA) for 4-6 h. Then we added the husband's pro-
cessed spermatozoa (0.3´106/mL). About 16-18 h later,
the oocytes were removed and checked for evidence of
fertilization. Three days later we evaluated the cleavage
rate and embryo quality. A conventional P administra-
tion was given for luteal support after retrieving oo-
cytes.13 On the third day, the women underwent trans-
abdominal ultrasound-guided transcervical embryo
transfer. Two weeks later we monitored the serum level
of b-hCG. If this was negative we stopped the use of P;
if the woman was clinically pregnant, P support was
maintained until 8 weeks after ET. Confirmation of
pregnancy and fetal sac numbers was done through ul-
trasound examination 1 month after ET.
In the experimental group, women were given Xiaoyao
powder combined with ovarian stimulation until the
day of hCG injection. The composition of the stock
Xiaoyao powder was: Chaihu (Radix Bupleuri Chinen-
sis) 15 g, Baishao (Radix Paeoniae Alba) 15 g, Danggui
(Radix Angelicae Sinensis) 15 g, Fuling (Poria) 15 g, Bai-
zhu (Rhizoma Atractylodis Macrocephalae) 15 g, Gancao
(Radix Glycyrrhizae) 6 g, Shengjiang (Rhizoma Zingib-
eris Recens) 6 g and Bohe (Herba Menthae Haplocalycis)
6 g. All the herbs were purchased from the Bethune In-
ternational Peace Hospital (Shijiazhuang, China), with
a conventional decoction of 300 mL divided into two
doses, taken in the morning and evening until the day
of hCG injection. The remaining protocol was the
same as in the control group.
Collection of follicular fluid and granulosa cells
After oocyte retrieval, the collected follicular fluid was
centrifuged (125 g, 5 min), and the supernatant was
stored at －70℃ . The remaining liquid was discarded
and the sediment was diluted with phosphate buffered
saline (PBS) to 5 mL. This was transferred to a new
centrifugal tube, and 5 mL of Human Lymphocyte
Separation Medium (Beijing Solarbio Science and
Technology Co. Ltd., Beijing, China) was added gently
and centrifuged (80 g, 20 min). A white cell layer in
the middle of the tube made up of granulosa cells was as-
pirated out, diluted with PBS and centrifuged (503 g,
5 min). The supernatant was discarded and the granu-
losa cells were snap-frozen in liquid nitrogen for 5 min
and stored at－80℃.
Clinical indices
The total dose of Gn, antral follicle count (AFC), endo-
metrial thickness, oocyte number, high quality embryo
rate, pregnancy rate and pregnancy complications of
the two groups were observed and compared.
GDF-9 content of follicular fluid
The GDF-9 content in follicular fluid was detected us-
ing western blotting (primary antibody from Santa
Cruz Biochemicals, Santa Cruz, CA, USA). Aliquots of
20 mL of follicular fluid were thawed at room tempera-
ture, then boiled for 10 min, subjected to sodium do-
decyl sulfate polyacrylamide gel electrophoresis, and
separated proteins were transferred to polyvinylidene
fluoride membranes and sealed for 1 h. The membrane
was placed in GDF-9 working fluid (1∶1000, Santa
Cruz Biochemicals, Santa Cruz, CA, USA) for reaction
overnight at 4℃ . Tris-buffered saline containing 0.1%
Triton X-100 (TBST) was used to wash the membrane
(3´10 min). After pouring off the TTBS buffer, the sec-
ond antibody was added at an appropriate dilution in
5 mL 0.5% blocking buffer. After rocking gently for
30 min, the second antibody solution was poured off
the membrane and it was washed twice for 10 min
with TTBS buffer. The developing reagent was added
and the membrane was rocked gently while develop-
ment was monitored. When the bands could be seen
clearly, development was stopped by washing the mem-
brane with three changes of distilled water for 30 min.
Enhanced chemiluminescence (ECL) with b-actin as
an internal control was measured using a UVP gel im-
aging analysis system (GDS-8000, UVP Co., San Ga-
briel, CA, USA).
GDF-9 mRNA expression in granule cells deter-
mined by reverse transcription-polymerase chain re-
action (RT-PCR) amplification
The primers were synthesized by Union Biotechnology
Co. Ltd. (Nantong, China). The primers were de-
signed to amplify mRNA from GDF-9 (forward 5¢-
TCTATCTGTTGGGCGAGGTG-3¢ and reverse 5¢-
TGAAGGAGGCTGGTCACATC-3¢). GAPDH (for-
ward 5¢-ACCACAGTCCATG-CCATCAC-3¢ and re-
verse 5¢-TCCACCACCCTGTTGCTG-3¢) was used
as an endogenous control for normalizing gene ex-
pression.
Total RNA extraction was performed using a Trizol pu-
rification kit (Life Technologies, Carlsbad, CA, USA)
following the manufacturer's protocol. The extracts
were transferred to a 1.5 mL microcentrifuge tube,
topped up with 200 mL chloroform: isoamyl alcohol
(49∶1). The RNA samples were incubated for 5 min
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(at 70℃), and then cooled on ice for 5 min. They were
centrifuged for 10 min (2012 g at 4℃), and the up-
per layer was transferred to another 1.5 mL micro-
centrifuge tube with an equal volume of isopropanol
and left at － 20℃ overnight. It was centrifuged for
20 min (2012 g at 4℃ ), the supernatant was re-
moved and 1 mL 75% ethanol was added, mixed gen-
tly, centrifuged for 10 min (2012 g at 4℃) and the pel-
let was dissolved in 20 mL DEPC-treated water.
The prepared reaction mixture (Table 1) was then add-
ed to the reverse transcription (RT) reaction tube for
50 min at 42℃ and maintained for 5 min at 95℃ for
RT inactivation. In the PCR reaction solution (which
is used with 1 mL RT product, 10 mL 2× Master Mix,
2 mL Primer and 7 mL H2O ), the cycle profile for the
first PCR step was an initial denaturation and poly-
merase activation for 4 min at 96℃, followed by 30 cy-
cles of 30 s at 94℃, 30 s at 58℃ and 30 s at 72℃. Fi-
nal extension was performed for 5 min at 72℃ . The
PCR products were subjected to agarose gel electropho-
resis (20 mg/mL). A gel scanning system was used to
measure the integrated optical density (UVP Co.). Tar-
get gene DNA fragment density values divided by the
reference GAPDH amplified fragment density value
was used as the GDF-9 mRNA expression indicator.
Statistical analysis
SPSS (version 13.0; IBM, Armonk, NY, USA) was
used for data processing. Numerical variables are re-
ported as the mean±standard deviation. The means of
two groups were compared with Student's t-test if the
data satisfied criteria for normality and homogeneity of
variance; otherwise, the rank-sum test was used. The
Chi-squared test was used to compare percentile data.
All reported P values are two-sided and P<0.05 was
considered significant.
RESULTS
Comparison of clinical data
The experimental group had a mean age of (29.1±2.5)
years versus (29.7 ± 2.0) years for the control group.
The AFC showed no significant difference (12.8 ± 2.2
vs 11.9 ± 3.7) between the two groups. In the experi-
mental group, the overall Gn dose was lower than in
the control group, whereas the high quality embryo
and pregnancy rates had higher tendencies than in the
control group, albeit not significantly. The oocyte num-
ber was greater in the experimental group than in the
control group, but this difference was also not
significant.
The experimental group had one case of miscarriage;
the control group had one case of ovarian hyperstimula-
tion syndrome (OHSS) and one miscarriage. The com-
plication rate was not significantly different between
the two groups (Tables 2, 3).
GDF-9 content in follicular fluid by western blotting
There was no difference in the expression of β-actin in
the two groups. In the experimental group, the GDF-9
content was 1.31±0.90, higher than 0.94±0.19 in the
control group and the difference was significant (P<
0.05). (Table 4, Figure 2).
GDF-9 mRNA expression in the granulosa cells by
RT-PCR
The expression of GAPDH between the two groups
showed no obvious difference. The expression level of
GDF-9 mRNA in the experimental group (1.31±0.90)
was significantly higher than in the control group
(0.94±0.19) (P<0.05) (Table 3, Figure 3).
DISCUSSION
As an important and essential oocyte-secreted factor in
the process of oocyte maturation, GDF-9 is mainly ex-
pressed in gonadal tissues in both oocytes and granulo-
sa cells.14 The regulation of GDF-9 is essential in follic-
ulogenesis, acting via in an autocrine manner to pro-
mote oocyte growth and differentiation, but also by af-
fecting the granulosa cells to regulate the entire follicu-
lar microenvironment. This is considered to be an im-
portant factor controlling follicular development and
ovulation.15-17 Huang et al 18 showed that the level of
GDF-9 is associated with oocyte and embryo quality
that can be used as index to predict the potential devel-
opment of embryo.
Traditional Chinese Medicine holds that the liver's
function is to store and disperse blood, which can regu-
late the Chong-thoroughfare and Ren-conception ves-
sels to maintain a woman's reproductive function. If
the liver's blood is deficient, the liver lacks nutrition
and liver-Qi is depressed and stagnant. Internal injury
by emotions, such as depression or anger, can also in-
jure the liver, or liver-Qi stagnation can transform into
heat retained inside the body. All of these factors can
cause the failure of the liver to function freely, resulting
in disharmony between Qi and the blood, and the
Chong and Ren vessels, thus the uterus cannot conserve
its essence to achieve pregnancy.
Table 1 Components for synthesis of cDNA first chain
Component
5´ RT buffer
dNTP
RNasin
RNA
Random primer
M-MLV
Nuclease-free water
Total
Volume (mL)
5
2.5
2
5.3
1
6
3.2
25
Concentration
1×
10 M
20 U/L
g
0.1 μg/L
5 U/L
-
-
Notes: cDNA: complementary deoxyribonucleicacid; RT buffer:
reverse transcriptase buffer; dNTP: deoxy-ribonucleoside tri-
phosphate; RNasin: RNase inhibitor; RNA: ribonucleic acid;
M-MLV: moloney murine leukemia virus.
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In daily medical practice, the application of dispersing
the stagnated liver-Qi has remarkable curative effect on
infertility.6,7 Therefore, in this study, Xiaoyao powder
was adopted as the representative prescription for liver
soothing. This is made up of Chaihu (Radix Bupleuri
Chinensis), Danggui (Radix Angelicae Sinensis), Baishao
(Radix Paeoniae Alba), Fuling (Poria), Baizhu (Rhizoma
Atractylodis Macrocephalae), Gancao (Radix Glycyrrhi-
zae), Shengjiang (Rhizoma Zingiberis Recens) and Bohe
(Herba Menthae Haplocalycis). In this prescription,
Chaihu (Radix Bupleuri Chinensis) plays an important
role to control liver-Qi and resolve depression, smooth
Qi and the blood and the thoroughfare and conception
vessels. It is considered to be a Jun-principal ingredi-
ent. Baishao (Radix Paeoniae Alba) can nourish blood,
sharpen Yin and soften the liver to relieve pain, where-
as Danggui (Radix Angelicae Sinensis) can enrich the
blood, promote blood circulation and regulate men-
struation, both of which are used to help liver function
and prevent Chaihu (Radix Bupleuri Chinensis) from
producing excessive catharsis, considered to be
Chen-adjuvant ingredients. Fuling (Poria), Baizhu (Rhi-
zoma Atractylodis Macrocephalae) and Gancao (Radix
Glycyrrhizae) can strengthen the Tu-spleen in transpor-
tation and transformation to produce Qi and blood
and at the same time restrain the Mu-liver. Shengjiang
(Rhizoma Zingiberis Recens) warms the stomach and
small quantities of Bohe (Herba Menthae Haplocalycis)
help Chaihu to sooth the liver and dispel stagnant
heat; both act as Zuo-correctant and Shi-conductant in-
gredients. Gancao (Radix Glycyrrhizae) coordinates the
actions of various ingredients, being also a Shi-conduc-
tant in this prescription. All the ingredients function
together to sooth the liver, to dispel stagnant heat, to
nourish and activate the blood to restore the functions
of the liver, and to strengthen the spleen and regulate
Table 2 Comparison of general conditions, Gn dose and endometrial thickness between the two groups ( xˉ ±s)
Group
Experiment
Control
P
n
30
28
-
Age
29.1±2.5
29.7±2.0
0.37
AFC
12.8±2.2
11.9±3.7
0.30
Endometrial thickness (mm)
9.7±1.4
8.8±0.6
0.004
Gn dose (IU)
1887.4±410.1
2005.7±309.8
0.023
Notes: the experimental group was treated with Xiaoyao powder plus ovarian stimulation with GnRHa/FSH/hCG; the control group only
received ovarian stimulation. Gn: gonadotripin; AFC: antral follicle count.
Table 3 Comparison of oocyte number, high quality embryo rate, pregnancy rate and pregnancy complication rate between the
two groups ( xˉ ±s)
Group
Experiment
Control
χ2
P
n
30
28
-
-
Oocyte numbers
14±4
13±3
-
0.232
High quality embryo rate (%)
74.1
61.7
8.3
0.004
Pregnancy rate (%)
70
42.8
4.4
0.037
Pregnancy complication rate (%)
6.7
3.6
0.283
0.595
Notes: the experimental group was treated with Xiaoyao powder plus ovarian stimulation with GnRHa/FSH/hCG; the control group only
received ovarian stimulation.
Table 4 Comparison of GDF-9 expression between the two
groups ( xˉ ±s)
Group
Experiment
Control
P
GDF-9
0.78±0.10
0.59±0.04
0.033
GDF-9 mRNA
1.31±0.90
0.94±0.19
0.037
Notes: the experimental group was treated with Xiaoyao powder
plus ovarian stimulation with GnRHa/FSH/hCG; the control
group only received ovarian stimulation. GDF-9: growth differ-
entiation factor-9; GDF-9 mRNA: growth differentiation fac-
tor-9 messenger ribonucleic acid.
Figure 3 RT-PCR electrophoretogram of GDF-9 mRNA expres-
sion in granulosa cells
GDF-9: growth differentiation factor-9. A-C: contro group;
D-F: experimental group.
bp
2000
1000750500
250
100
GDF-9
A B C D E
2000
1000750500
250
100
GAPDH
Figure 2 Western blot electrophoretogram of GDF-9 in follic-
ular fluid
A-C: contro group; D-F: experimental group. The experimen-
tal group was treated with Xiaoyao powder plus ovarian
stimulation with GnRHa/FSH/hCG; the control group only re-
ceived ovarian stimulation. GDF-9: growth differentiation
factor-9; GnRHa: gonadotropin-releasing hormone analog;
FSH: follicle-stimulating hormone; hCG: human chorionic
gonadotropin.
bp
734
838
GDF-9
β-actin
A B C D E F
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the Chong and Ren vessels; thus infertility is alleviated.
According to previous reports, Xiaoyao powder can
play an important role in improving reproductive func-
tion. On the one hand, it can improve pregnancy out-
come though regulating the anxious and depressive
state of patients undergoing IVF-ET.19-21 On the other
hand, it is capable of regulating the level of hormones,
improving ovarian function and promoting ovulation:
thus restoring the function of the ovary.22-24
In this research, Xiaoyao powder was applied at the
same time as ovulation stimulation. The result is that
the liver stagnation state of the patient was relieved, Qi
and the blood were regulated and the thoroughfare and
conception vessels unobstructed, consequently the oo-
cyte maturation, fertilization rate and high quality em-
bryo rate were all enhanced. Meanwhile, the liver's
store of blood was improved, and the flow of the
Chong and Ren vessels was sufficient to increase endo-
metrial thickness and improve the implantation rate.
In this study, the GDF-9 concentration in follicular flu-
id and GDF-9 mRNA expression in granulosa cells of
the experimental group were higher than those of the
control group, implying that Xiaoyao powder pro-
motes follicle growth, improves oocyte quality and in-
creases the clinical pregnancy rate, likely through in-
creasing the expression of the oocyte-secreted factor
GDF-9.
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